Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?
Publikation: Bidrag til tidsskrift › Leder › Forskning › fagfællebedømt
Standard
Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist? / Holst, Jens Juul.
I: The Lancet, Bind 394, Nr. 10192, 2019, s. 4-6.Publikation: Bidrag til tidsskrift › Leder › Forskning › fagfællebedømt
Harvard
Holst, JJ 2019, 'Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?', The Lancet, bind 394, nr. 10192, s. 4-6. https://doi.org/10.1016/S0140-6736(19)31350-9
APA
Holst, J. J. (2019). Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist? The Lancet, 394(10192), 4-6. https://doi.org/10.1016/S0140-6736(19)31350-9
Vancouver
Holst JJ. Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist? The Lancet. 2019;394(10192):4-6. https://doi.org/10.1016/S0140-6736(19)31350-9
Author
Bibtex
@article{7a05639db93249f5ba8627597a941d90,
title = "Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?",
author = "Holst, {Jens Juul}",
year = "2019",
doi = "10.1016/S0140-6736(19)31350-9",
language = "English",
volume = "394",
pages = "4--6",
journal = "The Lancet",
issn = "0140-6736",
publisher = "TheLancet Publishing Group",
number = "10192",
}
RIS
TY - JOUR
T1 - Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?
AU - Holst, Jens Juul
PY - 2019
Y1 - 2019
U2 - 10.1016/S0140-6736(19)31350-9
DO - 10.1016/S0140-6736(19)31350-9
M3 - Editorial
VL - 394
SP - 4
EP - 6
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 10192
ER -
ID: 225957791